Charles River Laboratories stock (US1591881009): Shareholders approve 2026 incentive plan
Published on 05/13/2026 at 14:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International, Inc. held its 2026 annual meeting of shareholders, where investors approved the 2026 Long-Term Incentive Plan and several other significant proposals, according to GuruFocus as of May 2026. This approval supports the company's executive compensation strategy. Separately, director Paul W. Graves received a stock award of 1,438 shares at $177.62 per share, boosting his holdings to 2,384 shares, per an SEC Form 4 filing reported by Stock Titan as of May 2026.
As of: 13.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Charles River Laboratories International, Inc.
- Sector/industry: Life sciences services
- Headquarters/country: United States
- Core markets: North America, Europe, Asia
- Key revenue drivers: Research models, safety assessment, discovery services
- Home exchange/listing venue: NYSE (CRL)
- Trading currency: USD
Official source
For first-hand information on Charles River Laboratories, visit the company’s official website.
Go to the official websiteCharles River Laboratories: core business model
Charles River Laboratories provides essential products and services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in drug discovery, development, and safety testing, supporting clients from early research through regulatory approval stages. Its integrated solutions help accelerate the path to market for new therapies.
Headquartered in Wilmington, Massachusetts, Charles River operates globally with a focus on research models and services, cell solutions, and discovery and safety assessment. This diversified model serves major biopharma firms, generating stable demand tied to R&D spending in healthcare.
Main revenue and product drivers for Charles River Laboratories
The company's revenue primarily comes from three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. RMS includes the production and sale of purpose-bred laboratory animals and related services, a foundational driver. DSA, the largest segment, offers preclinical testing and development support.
In recent years, Charles River has expanded into cell and gene therapy services, capitalizing on growing demand. For US investors, the firm's exposure to innovative biotech pipelines underscores its relevance amid rising healthcare R&D investments in the American market.
Industry trends and competitive position
The preclinical services sector benefits from surging biotech funding and regulatory pressures for robust safety data. Charles River holds a leading position with its end-to-end platform, competing with firms like Labcorp Drug Development and Eurofins. Its scale and expertise in non-human primates and genetically modified models provide a competitive edge.
Why Charles River Laboratories matters for US investors
Listed on the NYSE under ticker CRL, Charles River Laboratories offers US investors direct access to the booming life sciences tools sector. With significant revenue from North American clients, including top US pharmas, the stock reflects domestic biotech health and FDA approval trends.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Conclusion
The approval of the 2026 Long-Term Incentive Plan at the annual meeting signals continuity in Charles River Laboratories' governance and compensation practices. Combined with recent director stock awards, these developments highlight ongoing alignment between management and shareholders. Investors will watch how these elements support the company's role in preclinical services amid evolving biotech demands.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
